October 2023 - Page 12 of 16

Two Studies of Dr. Yong Xu’s Teamat the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

By Peter W. PENG 2023.10.12

The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year's EAU Congress, Dr. Yong Xu's team from the Second Hospital of Tianjin Medical University had two related studies on prostate cancer selected for presentation, exploring radical excision surgery without biopsies for highly suspicious prostate cancer patients and comparing regional saturation biopsies to targeted biopsies for initial evaluation of suspected prostate cancer patients. These research findings offer new perspectives on prostate cancer biopsies and non-invasive diagnostics.

Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

By Peter W. PENG 2023.10.12

The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology and discussing the latest advances in hematology. In the treatment of acute lymphoblastic leukemia (ALL), there was significant progress made at this EHA meeting, mainly focused on immunotherapy. To further grasp the content in this area, Oncology Frontier interviewed Professor Ma Jun from the Harbin Institute of Hematology & Oncology and discussed this topic in detail.

Two renal cancer-related studies by Dr. KanGong ‘s team selected for the 2023 EAU Annual Meeting

By Peter W. PENG 2023.10.12

The 38th European Association of Urology Annual Meeting (EAU23) was held in Milan, Italy, the world's fashion capital, from March 10 to 13, 2023. The EAU annual conference is one of the most closely watched urology conferences in Europe and even globally, attracting over 15,000 urology experts worldwide every year. At this EAU conference, two kidney cancer-related studies from the team of Dr Kan Gong of Peking University First Hospital were selected for discussion. The research indicates that the age of first onset is an independent risk factor affecting the prognosis in patients with large fragment deletions of Von Hippel-Lindau (VHL) syndrome. These patients may benefit from tyrosine kinase inhibitor (TKI) treatment. Initial CD4+T cells and memory CD4+T cells may be specific immune cells infiltrating VHL syndrome-related kidney cancer, and their infiltration level is closely related to VHL protein expression and patient prognosis.

Dr. HuiqiangHuang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.

By Peter W. PENG 2023.10.12

Extranodal NK/T-cell lymphoma (ENKTCL) of nasal type is a rare subtype, commonly found in the Asian population and associated with the Epstein-Barr Virus (EBV). At present, the prognosis for patients remains poor, especially for relapsed/refractory (R/R) cases. From June 8 to 11, 2023, the 28th European Hematology Association (EHA) annual meeting was held in Frankfurt, Germany. A selected oral report (Abstract No.: S226) from the conference showed that the use of PD-1 inhibitors alone or in combination significantly improved the treatment of R/R ENKTCL patients. This study further confirmed that immune checkpoint inhibitors have become an important treatment option for R/R ENKTCL patients. Oncology Frontier invited Dr. Huiqiang Huang from Sun Yat-sen University Cancer Center to share the research findings and insights at the conference.

Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia

By Peter W. PENG 2023.10.12

T-cell lymphoblastic lymphoma (T-LBL) is a highly malignant and rare lymphoma with aggressive behavior. It primarily affects adolescents, often presenting with mediastinal lymph node enlargement and commonly accompanied by pericardial and pleural effusions. In some cases, the disease can involve the central nervous system (CNS) with neurological manifestations. About 20% of patients progress to acute T-cell lymphoblastic leukemia (T-ALL) in advanced stages, which has a rapid progression and poor prognosis.

Dr. QianJiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

By Peter W. PENG 2023.10.12

From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.

$Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases at 2023 EHA$

Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases at 2023 EHA

By Peter W. PENG 2023.10.12

The 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany, from June 8 to 11, 2023. Dr Xiaofan Zhu and his team from the Children's Hematology Center at the Chinese Academy of Medical Sciences and Peking Union Medical College presented four abstracts at this EHA congress. These abstracts covered various aspects of research, including the prognostic factors for relapsed childhood acute lymphoblastic leukemia (ALL) treated with the CCLG-ALL2008 protocol in China, the use of Blinatumomab for 14 days in combination with chemotherapy to achieve minimal residual disease (MRD) conversion in pediatric B-ALL patients, the integration of transcriptomic features to improve prognosis prediction in pediatric acute myeloid leukemia (AML) with KMT2A rearrangements, and the effective treatment of pediatric non-sickle cell anemia (NSAA) with Hydroxyurea in combination with CSA. To gain a deeper understanding of these studies, Dr. Zhu has provided interpretations of the research findings, which are summarized below.

Dr. Liu Hongxing and Wang Tong: Decoding Structural Aberrations of the PAX5 Gene in B-ALL and its Correlation with Diagnostic Classification and Treatment Outcomes

By Peter W. PENG 2023.10.12

Acute B lymphoblastic leukemia (B-ALL) is a clonal heterogeneous disease caused by mutations in genes associated with the development and proliferation of B lymphocytes, which obstructs the normal differentiation and maturation of B lymphocyte progenitor cells. Although the complete remission rate for adult ALL patients can exceed 80% after induction remission therapy, most patients eventually relapse, resulting in a low long-term survival rate. Recently, many new gene mutation types have been detected in relapsed B-ALL patients using technologies such as gene chips and second-generation sequencing. However, the exact pathogenesis of these gene mutations and their co-synergistic fusion genes in B-ALL remains unclear. At the recently concluded 28th European Hematology Association (EHA) annual meeting, a study (Abstract No: P346) by the team of Liu Hongxing and Wang Tong from Beijing Lu Daopei Hematology Institute was selected for this year's EHA. The research aims to decode the structural changes of PAX5 and analyze other pathological fusion genes and gene mutations in B-ALL, while following up on the treatment and outcome of patients.

Dr. Jie Jin: the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

By Peter W. PENG 2023.10.12

The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.

Dr. HuilaiZhang’s Team: Key Research in the Field of Hodgkin Lymphoma

By Peter W. PENG 2023.10.12

The 28th European Hematology Conference/Annual Meeting (28th EHA Congress) was successfully held in Frankfurt, Germany from June 8-11, 2023. The conference was organized by the European Hematology Association (EHA). As one of the largest international conferences in the field of hematology worldwide, the EHA annual meeting gathered top hematology experts from around the globe, covering all aspects of hematology research. The conference featured oral presentations, poster presentations, and several other sessions. This edition of Oncology Frontier focuses on key clinical studies on Hodgkin lymphoma presented in the oral report session, providing a quick overview of the latest research advancements in this area.